GLIPIZIDE

Description_x000D_ General description_x000D_ Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1). Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5)_x000D_ Application_x000D_ Glipizide has been used in:_x000D_ • chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assay_x000D_ • MCF-7 breast cancer assay on chorioallantoic membrane (CAM)_x000D_ • metastasis assays_x000D_ • rat aortic ring assay_x000D_ • in vivo matrigel plug assay_x000D_ • 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay_x000D_ • flow cytometry_x000D_ • western blotting_x000D_ Packaging_x000D_ 1 g in poly bottle_x000D_ 500 mg in poly bottle_x000D_ Biochem/physiol Actions_x000D_ Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance. It is an ATP-dependent K+ channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC). Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes. Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC